Long-term effects of discontinuing renin-angiotensin system inhibitors in COVID-19.
作者信息
Theurl Fabian, Sappler Nikolay, Rizas Konstantinos D, Massberg Steffen, Bauer Axel, Schreinlechner Michael
机构信息
Department of Internal Medicine III, Cardiology & Angiology, Medical University of Innsbruck, Innsbruck, Austria.
Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany.
出版信息
Respirology. 2022 Sep;27(9):788-790. doi: 10.1111/resp.14306. Epub 2022 Jun 7.
Abstract
摘要
相似文献
1
Long-term effects of discontinuing renin-angiotensin system inhibitors in COVID-19.停用肾素-血管紧张素系统抑制剂对新型冠状病毒肺炎的长期影响。
Respirology. 2022 Sep;27(9):788-790. doi: 10.1111/resp.14306. Epub 2022 Jun 7.
2
Increased Mortality in Antecedent Combined Renin-Angiotensin System Inhibitors and Antiplatelets Compared With Antiplatelets Alone in Hospitalized Patients With COVID-19.与单独使用抗血小板药物相比，住院 COVID-19 患者中联合使用肾素-血管紧张素系统抑制剂和抗血小板药物会增加死亡率。
Am J Ther. 2021 Jun 25;28(5):e587-e590. doi: 10.1097/MJT.0000000000001410.
3
Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.高血压，COVID-19 中的一个动态目标：当前观点和视角。
Circ Res. 2021 Apr 2;128(7):1062-1079. doi: 10.1161/CIRCRESAHA.121.318054. Epub 2021 Apr 1.
4
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.肾素-血管紧张素-醛固酮抑制剂与 COVID-19 感染。
Curr Hypertens Rep. 2022 Oct;24(10):425-433. doi: 10.1007/s11906-022-01207-3. Epub 2022 Jun 18.
5
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.血管紧张素转换酶 2 和肾素血管紧张素系统抑制剂在 COVID-19 中的应用：最新进展。
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
6
Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.抗高血压药物的停用对因严重急性呼吸综合征冠状病毒 2 住院患者结局的影响。
Hypertension. 2021 Jul;78(1):165-173. doi: 10.1161/HYPERTENSIONAHA.121.17328. Epub 2021 Jun 9.
7
Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?肾素-血管紧张素系统抑制剂能否预防重症新型冠状病毒肺炎？
Hypertension. 2021 Mar 3;77(3):843-845. doi: 10.1161/HYPERTENSIONAHA.120.16800. Epub 2021 Feb 10.
8
Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂治疗新型冠状病毒肺炎有效性和安全性的系统评价和 Meta 分析
J Am Heart Assoc. 2022 Sep 6;11(17):e026143. doi: 10.1161/JAHA.122.026143. Epub 2022 Aug 24.
9
Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.在2019冠状病毒病大流行期间，使用血管紧张素II受体阻滞剂或血管紧张素转换酶抑制剂治疗高血压。
Expert Rev Cardiovasc Ther. 2021 Jan;19(1):99-100. doi: 10.1080/14779072.2021.1842050. Epub 2020 Nov 12.
10
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.血管紧张素-肾素-醛固酮系统抑制剂与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
JAMA Netw Open. 2021 Mar 1;4(3):e213594. doi: 10.1001/jamanetworkopen.2021.3594.
引用本文的文献
1
Treating COVID-19: Targeting the Host Response, Not the Virus.治疗新冠病毒病：针对宿主反应，而非病毒。
Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.
2
Letter from Austria.来自奥地利的信。
Respirology. 2022 Oct;27(10):903-904. doi: 10.1111/resp.14330. Epub 2022 Jul 14.
Zotero 插件